Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX DESCRIBES NEW TECHNOLOGY TO IDENTIFY CANCER TARGETS

Rochester, N.Y. August 14, 2001 In the current issue of Nature Medicine, a leading biomedical journal, Vaccinex scientists describe a novel and highly efficient technology for the identification of molecules present in tumor cells called antigens. These antigens can serve as targets of immunity and are key components of vaccines for the treatment of cancer. The lead author of the report is Dr. Ernest Smith, Research Director at Vaccinex. Dr. Smith and colleagues developed the technology to identify antigens that are shared by tumors in different individuals and that could become the basis for broadly effective cancer vaccines. The key innovation in this technology is a novel method for creating a large collection of genes from which individual genes with specific biological functions can be selected. According to Dr. Smith, "This technology is unique in its ability to identify genes that regulate many of the important biological processes that result in cessation of cell growth or cell death.", In addition to identifying the target molecules on cancer cells that can be recognized by cytotoxic immune cells, Vaccinex has adapted this technology to selection of therapeutic human antibodies, and to identification of genes that regulate differentiation of stem cells of the musculoskeletal sysytem.

Vaccinex, Inc., headquartered in Rochester, New York, is a privately owned biopharmaceutical company engaged in the development of a wide variety of vaccines and medicinal agents to treat cancers and infectious diseases. Founded in 1997, the company is at the forefront of the genomics revolution, leveraging powerful proprietary research tools to identify target genes involved in the development of a wide variety of diseases, and then using this newly acquired knowledge to develop effective therapies.

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX DESCRIBES NEW TECHNOLOGY TO IDENTIFY CANCER TARGETS Rochester, N.Y. August 14, 2001 In the current issue of Nature Medicine, a leading biomedical journal, Vaccinex scientists describe a novel and highly efficient technology for the identification of molecules present in tumor cells called antigens. These antigens can serve as targets of immunity and are key components of vaccines for the treatment of cancer. The lead author of the report is Dr. Ernest Smith, Research Director at Vaccinex. Dr. Smith and colleagues developed the technology to identify antigens that are shared by tumors in different individuals and that could become the basis for broadly effective cancer vaccines. The key innovation in this technology is a novel method for creating a large collection of genes from which individual genes with specific biological functions can be selected. According to Dr. Smith, "This technology is unique in its ability to identify genes that regulate many of the important biological processes that result in cessation of cell growth or cell death.", In addition to identifying the target molecules on cancer cells that can be recognized by cytotoxic immune cells, Vaccinex has adapted this technology to selection of therapeutic human antibodies, and to identification of genes that regulate differentiation of stem cells of the musculoskeletal sysytem. Vaccinex, Inc., headquartered in Rochester, New York, is a privately owned biopharmaceutical company engaged in the development of a wide variety of vaccines and medicinal agents to treat cancers and infectious diseases. Founded in 1997, the company is at the forefront of the genomics revolution, leveraging powerful proprietary research tools to identify target genes involved in the development of a wide variety of diseases, and then using this newly acquired knowledge to develop effective therapies. Back to News Archive Copyright © 2008 Vaccinex, Inc.